Patents Examined by David K O'Dell
  • Patent number: 11912696
    Abstract: Disclosed herein are compounds that can be used to selectively detect nitric oxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting nitric oxide using the compounds.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: February 27, 2024
    Assignee: Promega Corporation
    Inventors: Matthew A. Larsen, Hui Wang, Wenhui Zhou, Peter Hofsteen, Jolanta Vidugiriene
  • Patent number: 11912659
    Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: February 27, 2024
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
  • Patent number: 11909047
    Abstract: The present invention relates to an oligomer-based organic battery materials, cathode active material, cathode and secondary battery comprising such material, and a process for preparing such materials.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: February 20, 2024
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Yu Zhao, Gaole Dai, Yumin Qian, Xiaohong Zhang
  • Patent number: 11905284
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: February 20, 2024
    Assignee: PFIZER INC.
    Inventors: Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
  • Patent number: 11905247
    Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: February 20, 2024
    Assignee: XWPHARMA LTD.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Xianbo Liu, Wai-Si Eng
  • Patent number: 11897890
    Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R1 is C1-C3alkyl optionally substituted with F, C3-C6cycloalkyl, C1-C3alkoxy; X represents a bond or C1-C3alkylene optionally substituted with OH, ONO, ONO2; R2 is H, OH, ONO, ONO2, C(O)OH, C(O)OC1-C3alkyl, CHO, CN, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl, CR8?N—OR9, CR8?N—NR10R11, CR8?NR12 or CR8?N—ONO2; R3 is C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, C1-C3alkoxy, C3-C6cycloalkyl; C3-C6cycloalkyl, C2-C6alkenyl, C2-C6alkynyl; R4 is C1-C6alkyl optionally substituted with C3-C6cycloalkyl, C1-C6alkoxy, F, ONO, ONO2; C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl; R5 is H, SO2NR13R14, NHSO2NR13R14; R6 is H or C1-C3alkyl; R7 is H, C1-C3alkyl, C1-C3alkoxy, C1-C3alkyl substituted with phenyl, benzyl or a heterocyclic ring, wherein said phenyl, benzyl or said
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: February 13, 2024
    Assignee: TOPADUR PHARMA AG
    Inventors: Reto Naef, Hermann Tenor
  • Patent number: 11897895
    Abstract: This invention relates to a process for preparing (±)-2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane of the formula (I), any one of its individual enantiomers or any non-racemic mixture thereof any one of its individual enantiomers or any non-racemic mixture thereof, comprising the steps of (a) reacting (±)-2-exo-hydroxy-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane of the formula (II), any one of its individual enantiomers or any non-racemic mixture thereof (as defined in the description) with elemental sodium to form a sodium salt of the formula (III), any one of its individual enantiomers or any non-racemic mixture thereof (as defined in the description), and (b) reacting said sodium salt (III) with a 2-Methylbenzyl compound of the formula (IV) wherein X is a leaving group, wherein the steps (a) and (b) are conducted in the presence of at least one substantially anhydrous inert organic solvent.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: February 13, 2024
    Assignee: BASF AGRO B.V.
    Inventors: Michael Rack, Stefan Benson, Bernd Wolf, Roland Goetz
  • Patent number: 11884628
    Abstract: Disclosed is a simple synthesis method of lactam derivatives, comprising: with formamide functioning as both an amine source and a hydrogen source (hydrolyzed to produce formic acid), carrying out a cycloamination reaction on a raw material keto acid in the absence of a solvent or a catalyst to simply synthesize a lactam derivative. Compared with previous reports, the present disclosure has the following advantages: the time required for the reaction is greatly shortened, the selectivity is remarkably improved, a conversion rate of a keto acid derivative is greater than 99%, and the yield of the lactam derivative can reach 70% to 94%.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: January 30, 2024
    Assignee: GUIZHOU UNIVERSITY
    Inventors: Song Yang, Hu Li, Hongguo Wu
  • Patent number: 11866443
    Abstract: The present invention relates to a method for separating an optically active hydroxy cineole derivatives by lixiviation and crystallization and enantiomerically pure optically active hydroxy cineole derivatives of purity greater than 99.5% that have been prepared by this process. The present invention further relates to use of the desired enantiomer having enantiomeric excess of at least 99.5% ee as prepared according to the present invention, for the synthesis of enantiomerically pure 7-oxabicyclo[2.2.1]heptane derivatives.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: January 9, 2024
    Assignee: BASF AGRO B.V.
    Inventors: Klaus Ditrich, Michael Rack, Stefan Benson, Roland Goetz, Helmut Kraus
  • Patent number: 11866418
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: January 9, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Patent number: 11851439
    Abstract: The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' engagement of the opioid receptors when given orally. A 3-hexadienoate modification of nalbuphine or a pharmaceutically acceptable salt of thereof to improve quality of pain management when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation. A 3-hexadienoate modification of the opioids antagonists is formulated to improve inhibition of the opioid receptors when given orally. A 3-hexadienoate modification of naloxone or a pharmaceutically acceptable salt of thereof to improve quality of Sobering when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: December 26, 2023
    Assignee: Kappa-Pharma LLC
    Inventors: Georgiy Nikonov, Levon Isakulyan, Michael Voronkov
  • Patent number: 11845731
    Abstract: The application describes methods for making a deuterated dextromethorphan of Formula (I), deuterated dextromethorphan produced by these methods, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: December 19, 2023
    Assignee: AVANIR PHARMACEUTICALS, INC.
    Inventors: Matt Johnson, Cunxiang Zhao, Weihua Meng, Zhijun Lu, Yan Li
  • Patent number: 11840522
    Abstract: A method of stabilizing perfluoro(2-methylene-4-methyl-1,3-dioxolane) (hereinafter simply referred to as a “stabilization method”), including incorporating at least one selected from the group consisting of a hydroxy group-containing fluoroaromatic compound represented by General Formula (1) below and a hydroxy group-containing fluoroaromatic compound represented by General Formula (2) below into a composition containing perfluoro(2-methylene-4-methyl-1,3-dioxolane): (in the formula, R1 to R6 each independently represent one selected from the group consisting of a fluorine atom, a perfluoroalkyl group and a hydroxy group, and at least one of R1 to R6 is a hydroxy group); (in the formula, R7 to R14 each independently represent one selected from the group consisting of a fluorine atom, a perfluoroalkyl group and a hydroxy group, and at least one of R7 to R14 is a hydroxy group).
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: December 12, 2023
    Assignees: TOSOH CORPORATION, TOSOH FINECHEM CORPORATION
    Inventors: Hideki Miyauchi, Shota Nishida, Daisuke Inoue, Yusuke Shigeta, Norihisa Kondo, Makoto Watanabe, Shohei Yumino, Tomoya Shimono
  • Patent number: 11840495
    Abstract: The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: December 12, 2023
    Assignees: The Broad Institute, Inc., Instituto Carlos Slim de la Salud, A.C., Brigham and Women's Hospital, Inc.
    Inventors: Brian T. Chamberlain, David Kornfilt, Florence F. Wagner, Maria Alimova, Anna Greka, Joseph Growney
  • Patent number: 11827601
    Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: November 28, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei Ikeda, Makoto Kamata, Yuya Oguro
  • Patent number: 11826316
    Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: November 28, 2023
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
  • Patent number: 11820751
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 21, 2023
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Patent number: 11820746
    Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: November 21, 2023
    Assignee: UCB PHARMA GMBH
    Inventors: Christa E. Mueller, Cécile Pegurier, Michael Louis Robert Deligny, Ali El-Tayeb, Joerg Hockemeyer, Marie Ledecq, Joël Mercier, Larurent Provins, Nader M. Boshta, Sanjay Bhattarai, Vigneshwaran Namasivayam, Mario Funke, Lukas Schwach, Sabrina Gollos, Daniel Von Laufenberg, Anaïs Barré
  • Patent number: 11807651
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: November 7, 2023
    Assignees: Loxo Oncology Inc., Array BioPharma Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • Patent number: 11807618
    Abstract: The present invention relates to a new class of compounds having an antiviral effect and the uses thereof.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: November 7, 2023
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoît De Chassey, Laëtitia Lines, Jérôme Amaudrut, Benaissa Boubia, Vincent Derain, Fabrice Guillier, Christian Montalbetti, Calum Macleod, Karine Fabienne Malagu, David Robert Vesey, Paul Colin Michael Winship